CD5 and diffuse large B-cell lymphoma: In addition, our study included patients with stages I and II WR‐DLBCL and LN‐DLBCL, which may explain why the frequencies of MYC, BCL2, p53, and CD5 expression were lower in each subgroup than in the literature describing the expression patterns of MYC, BCL2, p53, and CD5 in DLBCL (often stage III/IV).